deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05019716

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

A Phase 1 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Platinum-based Chemotherapy in Patients With NUT Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Advanced NUT Carcinoma Metastatic NUT Carcinoma Unresectable NUT Carcinoma
Interventions BET Bromodomain Inhibitor ZEN-3694 Biopsy Procedure Biospecimen Collection Carboplatin Cisplatin Etoposide Imaging Procedure Paclitaxel
Updated 33 times since 2021 Last updated: Mar 12, 2026 Started: Jul 13, 2022 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05019716, this PHASE1/PHASE2 trial focuses on Advanced NUT Carcinoma and Metastatic NUT Carcinoma and remains actively recruiting participants. Sponsored by National Cancer Institute (NCI), it has been updated 33 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Apr 2025 · 4 months · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Oct 2025 · 2 months · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

33 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1 → PHASE1/PHASE2

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE1

    Phase: PHASE1/PHASE2 → PHASE1

  4. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE1/PHASE2

  5. Aug 2025 — Oct 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 28 earlier versions

  1. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Dec 2024 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  6. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  7. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  8. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  9. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  10. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  14. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  15. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  16. Aug 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  19. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  20. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  21. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  22. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Apr 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  26. Nov 2021 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  27. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  28. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations